Sun Xianzue
Deputy Commissioner, State Food and Drug Administration (SFDA)

Sun Xianze has been serving as Deputy Commissioner of the SFDA since September 2012.

VC Sun has a long a prestigious career with the SFDA, serving as the Director of the Information Center of the Drug Supervision Management Bureau prior to being appointed VC of the SFDA. Before that, he served as the Director General of the Department for Drug Supervision (2009 – 2011) and the DG of the Department of Food Safety Supervision (2008 – 2009), and DG of the Food Safety Coordination Department (2003 – 2008).

Prior to joining the SFDA, Sun served with the Sichuan Provincial Food and Drug Administration from 1991 to 2000, being appointed as the Deputy Bureau Chief in May 2000. He held that position until being promoted to the SFDA in 2003.

Born in Jiangsu Province in June 1957, Sun graduated with a bachelor’s degree from China Pharmaceutical University in Nanjing, Jiangsu Province in 1982.

Governor Jon M.  Huntsman Jr.

Jon Huntsman served as Ambassador to China from 2009 thru April, 2011 when he stepped down to run for the 2012 Republican nomination for President. Prior to serving as Ambassador to China, Huntsman was twice elected as Governor of Utah, including in 2008 with a record percent of the vote, including the majority in all 29 counties. As Governor, Huntsman governed with his eye toward maintaining Utah’s unparalleled quality of life, continually increasing the state’s economic competitiveness and maximizing funding to Utah’s public education system.

Huntsman’s breadth of experience in Asia has been developed over a lifetime of interest and involvement. He has previously lived in Asia four times and speaks fluent Mandarin Chinese.

Huntsman’s public service career began as a White House staff assistant to President Ronald Reagan and has since included appointments as Deputy Assistant Secretary of Commerce for Asia, U.S. Ambassador to Singapore and Deputy U.S. Trade Representative. As a U.S. Trade Ambassador, Huntsman negotiated dozens of free trade agreements, trade and investment framework agreements and brokered other bi-lateral and multi-lateral trade agreements for the United States with China, Taiwan, Singapore, Australia, India, Vietnam, West Africa, South Africa and other Asian and African nations. He played a critical role in launching global trade negotiations in Doha, Qatar in November of 2001, guiding the simultaneous accession of China and Taiwan into theWorld Trade Organization.

He is a founding director of the Pacific Council on International Policy and has served on various boards such as the Brookings Institute Asia Policy Board, the Center for Strategic and International Studies Pacific Forum, the Asia Society in New York and the National Bureau of Asian Research.

During his tenure as Governor, Utah was repeatedly recognized by many prestigious organizations for its dynamism, business climate and quality of life. Perhaps most importantly, Utah was named by the Pew Center as the Best Managed State in America. Even in times of economic hardship, Huntsman worked collaboratively with stakeholders to minimize impacts to critical human services while maintaining job-stimulating construction projects and keeping the State's Rainy Day Fund intact as a tool for any future fiscal distress.

Recognized nationally for his leadership, Huntsman served as chairman of the Western Governors Association and on the Executive Committee of the National Governors Association.

As a dedicated public servant, Huntsman is committed to serving in this critical post as Ambassador to one of the most important international relationships for the United States of America. He is a graduate of the University of Pennsylvania and has four honorary doctorate degrees.

Huntsman and his wife, Mary Kaye, live in Washington DC. They have seven children.

Perry Karsen
EVP, Chief Operations Officer, Celgene Corporation

Perry Karsen is an Executive Vice President  and currently serves as Chief Operations Officer at Celgene Corporation. Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held biotechnology company, from February 2009 until July 2010. Previously,  Mr. Karsen was Senior Vice President and Head of Worldwide Business Development at Celgene and was also responsible for emerging businesses as President, Asia/Pacific Region. Perry served as  Senior Vice President, Business Development at Human Genome Sciences; and earlier in his career, held positions including Vice President, Strategic Business Analysis and Development, Bristol-Myers Squibb; Senior Vice President Marketing and Sales, Zimmer, Inc.; Director, Business Development and Representative Director, Japan, at Genentech; and various domestic and international roles with Abbott Laboratories. Additionally, Mr. Karsen was a General Partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices.

Mr. Karsen serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO), the world’s largest biotechnology industry organization; a member of the Board of Directors of BayBio, representing the biotechnology industry in the San Francisco Bay Area; and a member of the Board of Directors for the Life Sciences Foundation, an organization dedicated to telling the story of biotechnology.  In addition, Mr. Karsen is a member of the Board of Directors of Agios Pharmaceuticals, a private biotechnology company pioneering research in cancer metabolism.

Mr. Karsen has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a BS in Biological Sciences from the University of Illinois, Urbana.

Peng Wang, Ph.D.
Chief Scientific Officer, Simcere

Dr. Peng Wang, a member of the China National “1000-Talents Program”, is currently Chief Scientific Officer of Simcere Pharmaceuticals Group, a leading Chinese pharmaceutical company headquartered in Nanjing, China (simcere.com; “SCR” at NYSE). Prior to joining Simcere, Dr. Wang was with WuXi PharmaTech (wuxiapptec.com; “WX” at NYSE), a leading pharmaceutical CRO in China, as Vice President of Discovery Biology in 2008-2009. Prior to joining WuXi PharmaTech, Dr. Wang worked on discovery through early clinical development for Schering-Plough in New Jersey, USA for 18 years. Dr. Wang has made significant contributions to discovery and early development of 16 drug candidates in US and China, and to establishment of several collaboration partnerships between Simcere and US companies. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J. etc. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, and his B.S. in Medicinal Chemistry from the China Pharmaceutical University.

Michael Rosenblatt, M.D.
Executive Vice President and Chief Medical Officer, Merck (MSD)

Scientist, educator, hospital and global healthcare company executive, Michael Rosenblatt, M.D., is executive vice president and chief medical officer at Merck. He is the company’s primary external advocate on medical issues and represents the voice of the patient inside Merck.

Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School; and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology.

Prior to these leadership positions, he was senior vice president for research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®). Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.

Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies and is a scientific founder of ProScript, Radius Pharmaceuticals and Theracrine.

Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of
Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.

He received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School.

Zhao Yajun
Director General, China Center for Pharmaceutical International Exchanges (CCPIE), State Food and Drug Administration (SFDA)

Mr. Zhao Yajun has been the DG of CCPIE since 2002, and prior to that Mr. Zhao Yajun was the Division Director of the International Cooperation Department of State Food and Drug Administration.

For a long time, Mr. Zhao Yajun has worked in international cooperation and has a lot experiences in international regulatory exchange.

Xu Zuxin
Deputy Director General, Science and Technology Commission of Shanghai Municipality

Ms. Xu Zuxin, currently the Deputy Director of the Science and Technology Commission of Shanghai Municipality (STCSM), has taken the position since September, 2007. She is now in charge of the Division of International Cooperation and Division of Bio-medicine, and assists administration of the Division of Basic Research.

Before that, Ms. Xu has successively served as the assistant to the President of Tongji University, executive deputy director for the leading group of environmental remediation and recovery for the Suzhou River in Shanghai, as well as the deputy director general and director general of the Shanghai Environmental Protection Bureau. Ms. Xu was born in Pingxiang, Jiangxi province.